Why Is Eli Lilly Suing the FDA Over Retatrutide's Classification?
TL;DR: Lilly is suing the FDA over whether retatrutide is a drug or a biologic — a fight that could reshape its 2027 filing.
What Is the Dispute Between Eli Lilly and the FDA About?
Separate from anything retatrutide has shown in the clinic, Eli Lilly and the FDA have spent nearly two years arguing over a narrower legal question: which regulatory category does retatrutide belong to for US marketing-approval purposes? The FDA has held that retatrutide is a chemically synthesised drug, reviewable under a New Drug Application (NDA). Lilly argues it is a biological product, entitled to review under a Biologics License Application (BLA) instead. Trade outlets including BioSpace and BioCentury describe the fight as unresolved and “coming to a head” as Lilly's target filing date approaches.[4]
This is a distinct story from the one covered in our report on Lilly's Q1 2027 filing delay, which was about manufacturing and quality-control (CMC) documentation. The classification lawsuit is about something that happens earlier in the process: which application form Lilly has to fill in, and what legal protections come attached to it once the drug is approved.
Velox Peptides supplies retatrutide as an HPLC-verified (≥99% purity) lyophilised reagent for in vitro research use only. View the product page →
How Did the Case Reach Court, and What's the Amino Acid Argument?
Eli Lilly filed suit against the FDA on 3 September 2024 in the US District Court for the Southern District of Indiana, in a case reported as Eli Lilly and Company v. Becerra, et al., No. 1:24-cv-01503, as first detailed by the law firm blogs Goodwin Law and Big Molecule Watch.[1][2]
The scientific crux is a bright-line rule. FDA regulation, drawn from the Biologics Price Competition and Innovation Act, defines a “protein” for licensing purposes as an alpha amino acid polymer with a specific, defined sequence greater than 40 amino acids. Per Lilly's own complaint, retatrutide's main backbone runs to 39 alpha amino acids, linked via an isopeptide bond to a second chain containing gamma-glutamate (itself an alpha amino acid) and ADO (8-amino-3,6-dioxaoctanoic acid) — a non-amino-acid spacer used, similarly to the design of tirzepatide and semaglutide, to attach a fatty-acid chain that extends the molecule's circulating half-life. Because ADO is not itself an amino acid, the FDA held the full molecule falls short of the >40 bright line and does not qualify as a protein outright. Lilly's position is that retatrutide is, at minimum, “analogous to a protein” — a category the same regulation separately allows for.[1]
| Date | Event |
|---|---|
| 3 Sep 2024 | Lilly files suit in S.D. Indiana challenging FDA's drug classification |
| 30 Sep 2025 | Court vacates FDA's decision as arbitrary; remands question to the agency |
| 13 Feb 2026 | Lilly files notice of appeal with the Seventh Circuit |
| Early Aug 2026 | Appeal and FDA remand both still pending; no new ruling issued |
What Did the September 2025 Ruling Actually Decide?
On 30 September 2025, the district court handed Lilly a partial win, but a narrower one than headlines sometimes suggest. The judge found the FDA's classification decision arbitrary and vacated it, then remanded the underlying question back to the agency, instructing it to apply a clearer, more consistent standard for when a molecule counts as “analogous to a protein.”[3]
Important nuance. The court did not rule that retatrutide is a biologic. It ruled only that the FDA's reasoning for calling it a drug was inadequate, and sent the agency back to redo the analysis. As of this writing, the classification question itself remains open — on remand at the FDA and, separately, on appeal at the Seventh Circuit.
What's Happening Now — the Seventh Circuit Appeal?
Not satisfied with a remand alone, Lilly filed a notice of appeal on 13 February 2026, asking the US Court of Appeals for the Seventh Circuit to go further and direct the FDA to classify retatrutide as a biologic outright, rather than simply reconsider its reasoning.[4]
As of early August 2026, neither the FDA's fresh remand determination nor a Seventh Circuit ruling has been issued. Trade press coverage frames the dispute as coming to a head precisely because it is running in parallel with Lilly's stated Q1 2027 target for filing retatrutide's US marketing application — the same timeline confirmed on 23 July 2026 alongside the TRIUMPH-2 and TRIUMPH-3 topline results covered in our CMC filing-delay report.[4][5] Whichever way the classification question resolves will determine whether Lilly ultimately submits a BLA or an NDA.
Why Does Drug vs Biologic Classification Matter So Much?
The stakes explain why a dispute over amino acid counting and linker chemistry has drawn sustained financial-press attention.
Market exclusivity
A BLA carries 12 years of regulatory exclusivity under the Biologics Price Competition and Innovation Act. An NDA, by contrast, typically carries five years of new-chemical-entity exclusivity under the Hatch-Waxman framework — a gap of seven years on the same molecule.
Medicare price-negotiation timing
Reporting has also tied the classification to the Inflation Reduction Act's Medicare drug price negotiation programme, under which small-molecule drugs become eligible for negotiation sooner (9 years post-approval) than biologics (13 years) — a difference press coverage has estimated could be worth tens of billions of dollars to Lilly over the product's commercial life.
None of this changes what retatrutide has reported in its completed Phase 3 trials; it is purely a question of which legal box the US government puts the finished drug in once approved.
Does This Affect the Filing Timeline or UK Research-Reagent Supply?
Not so far. Lilly's Q1 2027 filing target, confirmed 23 July 2026, has not shifted because of the classification fight — though which application type Lilly ultimately files could still hinge on how the Seventh Circuit appeal and the FDA's remand analysis land. It also does not touch the validity of the TRIUMPH-2 and TRIUMPH-3 data our trial results report covers.
The lawsuit is a US federal dispute about a licensed pharmaceutical company's future marketing application. It has no bearing on the UK regulatory position for research reagents, which sits under the Human Medicines Regulations 2012 and MHRA guidance — see our guide on whether research peptides are legal in the UK. It is also unrelated to the FDA's separate 503A compounding classification process for peptides like BPC-157 and TB-500, covered in our FDA peptide reclassification guide — that process concerns compounding pharmacy access, not a branded drug's licensing pathway. Retatrutide remains unlicensed for human use everywhere, regardless of how the classification question resolves.
Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Big Molecule Watch. Eli Lilly Files Suit Challenging the FDA's Drug Classification of Retatrutide. 24 September 2024. bigmoleculewatch.com
- Goodwin Law Insights. Eli Lilly Files Suit Challenging the FDA's Drug Classification of Retatrutide. September 2024. goodwinlaw.com
- Bloomberg Law. Lilly Gets Partial Win in Suit Over FDA's Biologic Determination. 30 September 2025. news.bloomberglaw.com
- BioSpace. Lilly, FDA Retatrutide Biologic Dispute Comes to a Head as Submission Nears. August 2026. biospace.com
- CNBC. Eli Lilly will file for approval of retatrutide obesity drug in 2027. 23 July 2026. cnbc.com
- Velox Peptides. Why Did Lilly Delay Retatrutide's FDA Filing to 2027? See our CMC filing-delay guide for the separate manufacturing-documentation story.
Frequently Asked Questions
Why is Eli Lilly suing the FDA over retatrutide?
Lilly sued because the FDA decided retatrutide does not meet the legal definition of a "protein" or biological product, meaning Lilly would have to file a New Drug Application (NDA) rather than the Biologics License Application (BLA) it wanted, which carries longer market exclusivity. Lilly filed suit in the Southern District of Indiana on 3 September 2024, as first reported by Goodwin Law and Big Molecule Watch.
What did the September 2025 court ruling decide?
On 30 September 2025, the district court found the FDA's classification decision arbitrary, vacated it, and remanded the question back to the agency to apply a clearer, more consistent standard for when a molecule is "analogous to a protein." The ruling did not declare retatrutide a biologic outright — it only sent the FDA back to redo its analysis.
What is the amino acid argument at the centre of the case?
FDA regulation defines a "protein" as an alpha amino acid polymer with a specific sequence greater than 40 amino acids. Per Lilly's complaint, retatrutide's main backbone has 39 alpha amino acids, linked via an isopeptide bond to a second chain containing gamma-glutamate and ADO (8-amino-3,6-dioxaoctanoic acid), a non-amino-acid spacer used to attach a fatty-acid chain that extends the molecule's half-life. Because ADO is not an amino acid, the FDA held the molecule falls short of the bright-line count; Lilly argues it is at minimum "analogous to a protein."
Where does the case stand as of August 2026?
Lilly filed a notice of appeal to the Seventh Circuit on 13 February 2026, seeking a ruling that directs the FDA to classify retatrutide as a biologic outright. As of early August 2026, trade press including BioSpace describe the dispute as unresolved and "coming to a head" as Lilly's Q1 2027 BLA/NDA filing target approaches, with neither a new FDA remand decision nor a Seventh Circuit ruling yet issued.
Does this lawsuit affect UK research-reagent supply of retatrutide?
No. This is a US federal legal dispute over which American regulatory pathway a licensed pharmaceutical company must use to seek marketing approval for its investigational drug. It has no bearing on the UK regulatory position for research reagents under the Human Medicines Regulations 2012. Velox Peptides supplies retatrutide as an HPLC-verified in vitro research reagent only, a status unrelated to this litigation. Order for research →